Vergelijking
Lixisenatide vs. Tirzepatide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
320367-13-3
2023788-19-2
Molecuulmassa
4858.5 g/mol
4813 g/mol
Halfwaardetijd
3 h
116 h
Sequentie
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSWerkingsmechanisme
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
4
waarvan bij mensen
5
4
Geregistreerde effecten
3
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Lixisenatide and Tirzepatide?
- Lixisenatide is classified as "Metabool", while Tirzepatide is classified as "Metabool". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Tirzepatide?
- The highest available evidence level is "Humane RCT" for Lixisenatide and "Humane RCT" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Tirzepatide in Germany and the United States?
- Duitsland: Lixisenatide — Op recept, Tirzepatide — Op recept. Verenigde Staten: Lixisenatide — Niet goedgekeurd, Tirzepatide — Op recept. These are factual summaries with source and review date on the individual pages.